We have updated the pathway: Tamoxifen PK pathway.

Tamoxifen is a selective estrogen receptor modulator. It is used to treat estrogen receptor positive breast cancer, and has been shown to decrease disease recurrence and mortality rates by 50% and 30%, respectively.

PharmGKB's Tamoxifen PK pathway describes the metabolism of tamoxifen from what can be classified as a pro-drug, to a more potent estrogen receptor inhibitor, and finally to its inactivation.

View or download the pathway here: Tamoxifen PK pathway.

View all pathways at PharmGKB.

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.